Applied Cells is pleased to announce the expansion of the MARS® Ingenuity™ line with the addition of CD34 Nanobeads, TCR α/β Nanobeads, and CD56 Nanobeads, now available in both RUO and GMP formats. Designed for use on the MARS® Bar
Santa Clara, California, and Bengaluru, India, January 13, 2026. Applied Cells Inc. announced today a strategic collaboration framework with Immuneel Therapeutics Private Limited to jointly evaluate the application of Applied Cells’ MARS® Atlas platform and GoFast™ CAR-T workflow for future
We’re excited to announce another significant milestone — Applied Cells has officially submitted a Type II Master File (MAF) for the MARS® Bar system to the U.S. Food and Drug Administration (FDA), under the Center for Biologics Evaluation and Research
We’re excited to share BIG NEWS — Applied Cells is now officially ISO 13485:2016 certified for the design and manufacture of sterile human cell separation systems intended for human cell therapy. This certification is a major milestone for our team
CAR-T cell therapies have shown great success in treating hematological cancers, including leukemia, lymphoma and multiple myeloma, by using genetically modified T cells to effectively attack cancer. However, as these therapies continue to transform cancer treatment, barriers to access remain
As we step into 2025, we are happy to announce that our study results were published in Cytotherapy journal. Co-authored with researchers from the University of Chicago Medical Center and CellReady, the publication highlights MARS® Bar — a new, column-free
